Chronic Lymphocytic Leukemia and Other Lymphoproliferative Disorders

Clinics in Geriatric Medicine

Volumn 32, Issue 1, 2016, Pages 175-189

  Wall, Sarah ^a   Woyach, Jennifer A ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

Chronic lymphocytic leukemia; Elderly; Non Hodgkin lymphoma

Indexed keywords

BENDAMUSTINE; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; FLUDARABINE; GEMCITABINE; IBRUTINIB; IDELALISIB; LENALIDOMIDE; OBINUTUZUMAB; OFATUMUMAB; PLACEBO; PREDNISONE; PROCARBAZINE; RITUXIMAB; VINCRISTINE;

AGING; ALLOGENEIC STEM CELL TRANSPLANTATION; ALOPECIA; CANCER PROGNOSIS; CHRONIC LYMPHATIC LEUKEMIA; CYTOGENETICS; DIARRHEA; FOLLICULAR LYMPHOMA; HEMATOLOGIC DISEASE; HUMAN; HYPERTENSION; INFECTION; KARYOTYPE; LARGE CELL LYMPHOMA; LYMPHOPROLIFERATIVE DISEASE; MANTLE CELL LYMPHOMA; MULTIPLE CYCLE TREATMENT; NONHODGKIN LYMPHOMA; PARESTHESIA; PATIENT MONITORING; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PREVALENCE; REVIEW; SOMATIC HYPERMUTATION; TREATMENT INDICATION; VACCINATION; AGED; COMORBIDITY; DISEASE MANAGEMENT; EVIDENCE BASED MEDICINE; GERIATRIC ASSESSMENT; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LYMPHOPROLIFERATIVE DISORDERS; RISK FACTOR; SOCIAL SUPPORT; VERY ELDERLY;

AGED; AGED, 80 AND OVER; COMORBIDITY; DISEASE MANAGEMENT; EVIDENCE-BASED MEDICINE; GERIATRIC ASSESSMENT; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LYMPHOPROLIFERATIVE DISORDERS; RISK FACTORS; SOCIAL SUPPORT;

EID: 84960415098     PISSN: 07490690     EISSN: 18798853     Source Type: Journal    
DOI: 10.1016/j.cger.2015.08.006     Document Type: Review

References (92)

1. Chronic lymphocytic leukemia - SEER stat fact sheets. 2015. Available at: . Accessed May 20, 2015. http://seer.cancer.gov/statfacts/html/clyl.html.
2. Thurmes P., Call T., Slager S., et al. Comorbid conditions and survival in unselected, newly diagnosed patients with chronic lymphocytic leukemia. Leuk Lymphoma 2008, 49:49-56.
3. Non-Hodgkin's lymphomas [Version 2.2015]. 2015. Available at: . Accessed May 20, 2015. http://www.nccn.org/professionals/physician_gls/pdf/nhl.pdf.
4. Shanafelt T.D., Ghia P., Lanasa M.C., et al. Monoclonal B-cell lymphocytosis (MBL): biology, natural history and clinical management. Leukemia 2010, 24:512-520.
5. Kalpadakis C., Pangalis G.A., Sachanas S., et al. New insights into monoclonal B-cell lymphocytosis. Biomed Res Int 2014, 2014:258917.
6. Moreira J., Rabe K.G., Cerhan J.R., et al. Infectious complications among individuals with clinical monoclonal B-cell lymphocytosis (MBL): a cohort study of newly diagnosed cases compared to controls. Leukemia 2012, 27:136-141.
7. Solomon BM, Rabe KG, Moreira J, et al. Risk of cancer in patients with clinical monoclonal B-cell lymphocytosis (MBL): A cohort study of newly diagnosed patients compared to controls. Poster presented at the 54th Annual Meeting of the American Society of Hematology. Atlanta, GA, December 8-11, 2012.
8. Binet J.L., Auquier A., Dighiero G., et al. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer 1981, 48:198-206.
9. Rai K.R., Sawitsky A., Cronkite E.P., et al. Clinical staging of chronic lymphocytic leukemia. Blood 1975, 46:219-234.
10. Juliusson G., Oscier D.G., Fitchett M., et al. Prognostic subgroups in B-cell chronic lymphocytic leukemia defined by specific chromosomal abnormalities. N Engl J Med 1990, 323:720-724.
11. Mayr C., Speicher M.R., Kofler D.M., et al. Chromosomal translocations are associated with poor prognosis in chronic lymphocytic leukemia. Blood 2005, 107:742-751.
12. Dohner H., Stilgenbauer S., Fischer K., et al. Cytogenetic and molecular cytogenetic analysis of B cell chronic lymphocytic leukemia: specific chromosome aberrations identify prognostic subgroups of patients and point to loci of candidate genes. Leukemia 1997, 11(Suppl 2):S19-S24.
13. Dohner H., Stilgenbauer S., Benner A., et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2001, 343:1910-1916.
14. Damle R.N., Wasil T., Fais F., et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 1999, 94:1840-1847.
15. Hamblin T.J., Davis Z., Gardiner A., et al. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 1999, 94:1848-1854.
16. Gribben J.G. How I treat CLL up front. Blood 2009, 115:187-197.
17. Molica S. Infections in chronic lymphocytic leukemia: risk factors, and impact on survival, and treatment. Leuk Lymphoma 1994, 13:203-214.
18. Manusow D., Weinerman B.H. Subsequent neoplasia in chronic lymphocytic leukemia. JAMA 1975, 232:267-269.
19. Hodgson K., Ferrer G., Pereira A., et al. Autoimmune cytopenia in chronic lymphocytic leukaemia: diagnosis and treatment. Br J Haematol 2011, 154:14-22.
20. Kjeldsberg C.R., Marty J. Prolymphocytic transformation of chronic lymphocytic leukemia. Cancer 1981, 48:2447-2457.
21. Schweighofer CD, Cymbalista F, Muller C, et al. Early versus deferred treatment with combined fludarabine, cyclophosphamide and rituximab (FCR) improves event-free survival in patients with high-risk Binet stage A chronic lymphocytic leukemia - first results of a randomized German-French cooperative phase III trial. Paper presented at the 55th Annual Meeting of the American Society of Hematology. New Orleans, LA, December 7-10, 2013.
22. Hallek M., Cheson B.D., Catovsky D., et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 2008, 111:5446-5456.
23. Karnofsky D., Burchenal J. The clinical evaluation of chemotherapeutic agents in cancer. Evaluation of chemotherapeutic agents 1949, 191-205. Columbia University Press, New York. C. MacCleod (Ed.).
24. Oken M.M., Creech R.H., Tormey D.C., et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982, 5:649-655.
25. Linn B.S., Linn M.W., Gurel L. Cumulative illness rating scale. J Am Geriatr Soc 1968, 16:622-626.
26. Hurria A., Wildes T., Blair S.L., et al. Senior adult oncology, version 2.2014: clinical practice guidelines in oncology. J Natl Compr Canc Net 2014, 12:82-126.
27. Extermann M., Hurria A. Comprehensive geriatric assessment for older patients with cancer. J Clin Oncol 2007, 25:1824-1831.
28. Eichhorst B., Goede V., Hallek M. Treatment of elderly patients with chronic lymphocytic leukemia. Leuk Lymphoma 2009, 50:171-178.
29. Eichhorst B, Fink A-M, Busch R, et al. Frontline chemoimmunotherapy with fludarabine (F), cyclophosphamide (C), and rituximab (R) (FCR) shows superior efficacy in comparison to bendamustine (B) and Rituximab (BR) in previously untreated and physically fit patients (pts) with advanced chronic lymphocytic leukemia (CLL): final analysis of an international, randomized study of the German CLL Study Group (GCLLSG) (CLL10 study). Paper presented at the 56th Annual Meeting of the American Society of Hematology. San Francisco, CA, December 6-9, 2014.
30. Hallek M., Fischer K., Fingerle-Rowson G., et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet 2010, 376:1164-1174.
31. Eichhorst B.F., Busch R., Stilgenbauer S., et al. First-line therapy with fludarabine compared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemia. Blood 2009, 114:3382-3391.
32. Woyach J.A., Ruppert A.S., Rai K., et al. Impact of age on outcomes after initial therapy with chemotherapy and different chemoimmunotherapy regimens in patients with chronic lymphocytic leukemia: results of sequential cancer and leukemia group B studies. J Clin Oncol 2012, 31:440-447.
33. Goede V., Fischer K., Busch R., et al. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Engl J Med 2014, 370:1101-1110.
34. Goede V., Fischer K., Engelke A., et al. Obinutuzumab as frontline treatment of chronic lymphocytic leukemia: updated results of the CLL11 study. Leukemia 2015, 29:1602-1604.
35. Hillmen P., Robak T., Janssens A., et al. Chlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukaemia (COMPLEMENT 1): a randomised, multicentre, open-label phase 3 trial. Lancet 2015, 385:1873-1883.
36. Byrd J.C., Brown J.R., O'Brien S., et al. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med 2014, 371:213-223.
37. Byrd J.C., Furman R.R., Coutre S.E., et al. Three-year follow-up of treatment-naive and previously treated patients with CLL and SLL receiving single-agent ibrutinib. Blood 2015, 125:2497-2506.
38. Furman R.R., Sharman J.P., Coutre S.E., et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med 2014, 370:997-1007.
39. Non-Hodgkin lymphoma - SEER stat fact sheets. 2015. Available at: . Accessed May 20, 2015. http://seer.cancer.gov/statfacts/html/nhl.html.
40. Williams J.N., Rai A., Lipscomb J., et al. Disease characteristics, patterns of care, and survival in very elderly patients with diffuse large B-cell lymphoma. Cancer 2015, 121:1800-1808.
41. Monnereau A., Troussard X., Belot A., et al. Unbiased estimates of long-term net survival of hematological malignancy patients detailed by major subtypes in France. Int J Cancer 2012, 132:2378-2387.
42. Morrison V.A., Hamlin P., Soubeyran P., et al. Diffuse large B-cell lymphoma in the elderly: impact of prognosis, comorbidities, geriatric assessment, and supportive care on clinical practice. An International Society of Geriatric Oncology (SIOG) expert position paper. J Geriatr Oncol 2014, 6:141-152.
43. Pfreundschuh M. How I treat elderly patients with diffuse large B-cell lymphoma. Blood 2010, 116:5103-5110.
44. Zhou Y., Wang H., Fang W., et al. Incidence trends of mantle cell lymphoma in the United States between 1992 and 2004. Cancer 2008, 113:791-798.
45. Aschebrook-Kilfoy B., Caces D.B., Ollberding N.J., et al. An upward trend in the age-specific incidence patterns for mantle cell lymphoma in the USA. Leuk Lymphoma 2013, 54:1677-1683.
46. Nabhan C., Aschebrook-Kilfoy B., Chiu B.C., et al. The impact of race, age, and sex in follicular lymphoma: a comprehensive SEER analysis across consecutive treatment eras. Am J Hematol 2014, 89:633-638.
47. Cheson B.D., Fisher R.I., Barrington S.F., et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol 2014, 32:3059-3068.
48. Barrington S.F., Mikhaeel N.G., Kostakoglu L., et al. Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group. J Clin Oncol 2014, 32:3048-3058.
49. Seam P., Juweid M.E., Cheson B.D. The role of FDG-PET scans in patients with lymphoma. Blood 2007, 110:3507-3516.
50. Ziepert M., Hasenclever D., Kuhnt E., et al. Standard International Prognostic Index remains a valid predictor of outcome for patients with aggressive CD20+ B-cell lymphoma in the rituximab era. J Clin Oncol 2010, 28:2373-2380.
51. Nooka A.K., Nabhan C., Zhou X., et al. Examination of the Follicular Lymphoma International Prognostic Index (FLIPI) in the National LymphoCare study (NLCS): a prospective US patient cohort treated predominantly in community practices. Ann Oncol 2012, 24:441-448.
52. Troch M., Wohrer S., Raderer M. Assessment of the prognostic indices IPI and FLIPI in patients with mucosa-associated lymphoid tissue lymphoma. Anticancer Res 2010, 30:635-639.
53. Heilgeist A., McClanahan F., Ho A.D., et al. Prognostic value of the Follicular Lymphoma International Prognostic Index score in marginal zone lymphoma: an analysis of clinical presentation and outcome in 144 patients. Cancer 2012, 119:99-106.
54. Nabhan C., Byrtek M., Rai A., et al. Disease characteristics, treatment patterns, prognosis, outcomes and lymphoma-related mortality in elderly follicular lymphoma in the United States. Br J Haematol 2015, 170:85-95.
55. Alizadeh A.A., Eisen M.B., Davis R.E., et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000, 403:503-511.
56. Choi W.W., Weisenburger D.D., Greiner T.C., et al. A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy. Clin Cancer Res 2009, 15:5494-5502.
57. Hans C.P., Weisenburger D.D., Greiner T.C., et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2003, 103:275-282.
58. Bertoni F., Ponzoni M. The cellular origin of mantle cell lymphoma. Int J Biochem Cell Biol 2007, 39:1747-1753.
59. Cohen J.B., Ruppert A.S., Heerema N.A., et al. Complex karyotype is associated with aggressive disease and shortened progression-free survival in patients with newly diagnosed mantle cell lymphoma. Clin Lymphoma Myeloma Leuk 2015, 15:278-285.e1.
60. Nodit L., Bahler D.W., Jacobs S.A., et al. Indolent mantle cell lymphoma with nodal involvement and mutated immunoglobulin heavy chain genes. Hum Pathol 2003, 34:1030-1034.
61. Navarro A., Clot G., Royo C., et al. Molecular subsets of mantle cell lymphoma defined by the IGHV mutational status and SOX11 expression have distinct biologic and clinical features. Cancer Res 2012, 72:5307-5316.
62. Persky D.O., Unger J.M., Spier C.M., et al. Phase II study of rituximab plus three cycles of CHOP and involved-field radiotherapy for patients with limited-stage aggressive B-cell lymphoma: Southwest Oncology Group study 0014. J Clin Oncol 2008, 26:2258-2263.
63. Pfreundschuh M., Schubert J., Ziepert M., et al. Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). Lancet Oncol 2008, 9:105-116.
64. Delarue R., Tilly H., Mounier N., et al. Dose-dense rituximab-CHOP compared with standard rituximab-CHOP in elderly patients with diffuse large B-cell lymphoma (the LNH03-6B study): a randomised phase 3 trial. Lancet Oncol 2013, 14:525-533.
65. Jantunen E., Canals C., Rambaldi A., et al. Autologous stem cell transplantation in elderly patients (> or =60 years) with diffuse large B-cell lymphoma: an analysis based on data in the European Blood and Marrow Transplantation registry. Haematologica 2008, 93:1837-1842.
66. Lazarus H.M., Carreras J., Boudreau C., et al. Influence of age and histology on outcome in adult non-Hodgkin lymphoma patients undergoing autologous hematopoietic cell transplantation (HCT): a report from the Center for International Blood & Marrow Transplant Research (CIBMTR). Biol Blood Marrow Transplant 2008, 14:1323-1333.
67. Niitsu N., Umeda M. Evaluation of long-term daily administration of oral low-dose etoposide in elderly patients with relapsing or refractory non-Hodgkin's lymphoma. Am J Clin Oncol 1997, 20:311-314.
68. Ohmachi K., Niitsu N., Uchida T., et al. Multicenter phase II study of bendamustine plus rituximab in patients with relapsed or refractory diffuse large B-cell lymphoma. J Clin Oncol 2013, 31:2103-2109.
69. Coleman M., Martin P., Ruan J., et al. Prednisone, etoposide, procarbazine, and cyclophosphamide (PEP-C) oral combination chemotherapy regimen for recurring/refractory lymphoma: low-dose metronomic, multidrug therapy. Cancer 2008, 112:2228-2232.
70. Corazzelli G., Capobianco G., Arcamone M., et al. Long-term results of gemcitabine plus oxaliplatin with and without rituximab as salvage treatment for transplant-ineligible patients with refractory/relapsing B-cell lymphoma. Cancer Chemother Pharmacol 2009, 64:907-916.
71. Witzig T.E., Vose J.M., Zinzani P.L., et al. An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma. Ann Oncol 2011, 22:1622-1627.
72. Bernard M., Tsang R.W., Le L.W., et al. Limited-stage mantle cell lymphoma: treatment outcomes at the Princess Margaret Hospital. Leuk Lymphoma 2012, 54:261-267.
73. Ghielmini M., Zucca E. How I treat mantle cell lymphoma. Blood 2009, 114:1469-1476.
74. Rummel M.J., Niederle N., Maschmeyer G., et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet 2013, 381:1203-1210.
75. Flinn I.W., van der Jagt R., Kahl B.S., et al. Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study. Blood 2014, 123:2944-2952.
76. Kluin-Nelemans H.C., Hoster E., Hermine O., et al. Treatment of older patients with mantle-cell lymphoma. N Engl J Med 2012, 367:520-531.
77. Wang M.L., Rule S., Martin P., et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med 2013, 369:507-516.
78. Maddocks K., Christian B., Jaglowski S., et al. A phase 1/1b study of rituximab, bendamustine, and ibrutinib in patients with untreated and relapsed/refractory non-Hodgkin lymphoma. Blood 2014, 125:242-248.
79. Coleman M., Martin P., Ruan J., et al. Low-dose metronomic, multidrug therapy with the PEP-C oral combination chemotherapy regimen for mantle cell lymphoma. Leuk Lymphoma 2008, 49:447-450.
80. Ghielmini M., Schmitz S.F., Cogliatti S., et al. Effect of single-agent rituximab given at the standard schedule or as prolonged treatment in patients with mantle cell lymphoma: a study of the Swiss Group for Clinical Cancer Research (SAKK). J Clin Oncol 2004, 23:705-711.
81. Bauwens D., Maerevoet M., Michaux L., et al. Activity and safety of combined rituximab with chlorambucil in patients with mantle cell lymphoma. Br J Haematol 2005, 131:338-340.
82. Brice P., Bastion Y., Lepage E., et al. Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d'Etude des Lymphomes Folliculaires. Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 1997, 15:1110-1117.
83. Ardeshna K.M., Smith P., Norton A., et al. Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial. Lancet 2003, 362:516-522.
84. Ardeshna K.M., Qian W., Smith P., et al. Rituximab versus a watch-and-wait approach in patients with advanced-stage, asymptomatic, non-bulky follicular lymphoma: an open-label randomised phase 3 trial. Lancet Oncol 2014, 15:424-435.
85. Michallet A.S., Lebras L.L., Bauwens D.D., et al. Early stage follicular lymphoma: what is the clinical impact of the first-line treatment strategy?. J Hematol Oncol 2013, 6:45.
86. Hainsworth J.D., Litchy S., Burris H.A., et al. Rituximab as first-line and maintenance therapy for patients with indolent non-Hodgkin's lymphoma. J Clin Oncol 2002, 20:4261-4267.
87. Martinelli G., Schmitz S.F., Utiger U., et al. Long-term follow-up of patients with follicular lymphoma receiving single-agent rituximab at two different schedules in trial SAKK 35/98. J Clin Oncol 2010, 28:4480-4484.
88. Kahl B.S., Hong F., Williams M.E., et al. Rituximab extended schedule or re-treatment trial for low-tumor burden follicular lymphoma: Eastern Cooperative Oncology Group protocol e4402. J Clin Oncol 2014, 32:3096-3102.
89. Gopal A.K., Kahl B.S., de Vos S., et al. PI3Kdelta inhibition by idelalisib in patients with relapsed indolent lymphoma. N Engl J Med 2014, 370:1008-1018.
90. A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 1993, 329:987-994.
91. Hoster E., Dreyling M., Klapper W., et al. A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood 2007, 111:558-565.
92. Solal-Celigny P., Roy P., Colombat P., et al. Follicular lymphoma International Prognostic Index. Blood 2004, 104:1258-1265.